Global Female Sexual Dysfunction Treatment Market 2019-2023
SKU ID : TNV-14439889 | Publishing Date : 26-Jun-2019 | No. of pages : 108
Detailed TOC of Global Female Sexual Dysfunction Treatment Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Non-hormonal therapy - Market size and forecast 2018-2023
Hormonal therapy - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Increasing R&D for treatment of sexual dysfunctions in women
Safety label changes for female sexual dysfunction therapy
Increasing use of drugs causing sexual dysfunctions in women
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AMAG Pharmaceuticals Inc.
Duchesnay Inc.
Emotional Brain BV
Novo Nordisk AS
Sprout Pharmaceuticals Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Non-hormonal therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Non-hormonal therapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Hormonal therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Hormonal therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: AMAG Pharmaceuticals Inc. - Vendor overview
Exhibit 44: AMAG Pharmaceuticals Inc. - Business segments
Exhibit 45: AMAG Pharmaceuticals Inc. - Organizational developments
Exhibit 46: AMAG Pharmaceuticals Inc. - Key offerings
Exhibit 47: Duchesnay Inc. - Vendor overview
Exhibit 48: Duchesnay Inc. - Key offerings
Exhibit 49: Emotional Brain BV - Vendor overview
Exhibit 50: Emotional Brain BV - Key offerings
Exhibit 51: Novo Nordisk AS - Vendor overview
Exhibit 52: Novo Nordisk AS - Business segments
Exhibit 53: Novo Nordisk AS - Organizational developments
Exhibit 54: Novo Nordisk AS - Geographic focus
Exhibit 55: Novo Nordisk AS - Segment focus
Exhibit 56: Novo Nordisk AS - Key offerings
Exhibit 57: Sprout Pharmaceuticals Inc. - Vendor overview
Exhibit 58: Sprout Pharmaceuticals Inc. - Key offerings
Exhibit 59: Validation techniques employed for market sizing
Exhibit 60: Definition of market positioning of vendors